Physician profile
David A Maddock
NPI 1871758185
$2,133.89
in general payments reported to CMS, 2019-2025
24 companies · $987 in 2025
The $987 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.43 · 2021: $105 · 2022: $490 · 2023: $247 · 2024: $265 · 2025: $987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $371.67 | 2022-2025 | Slynd |
| Astellas Pharma US INC | $283.10 | 2023-2025 | Veozah |
| Abbvie INC. | $258.90 | 2022-2025 | |
| Sage Therapeutics, LLC | $214.24 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $151.30 | 2022-2025 | |
| Myovant Sciences INC. | $82.77 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.88 | 2022-2025 | |
| Therapeuticsmd, INC. | $67.39 | 2021-2022 | |
| Coopersurgical, INC. | $65.59 | 2022-2025 | Paragard T 380a |
| Mylan Pharmaceuticals INC. | $55.93 | 2022 | |
| Sumitomo Pharma America, INC. | $54.54 | 2023-2025 | Myfembree, Gemtesa |
| Mayne Pharma Commercial LLC | $51.82 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $47.59 | 2025 | Qelbree |
| Daiichi Sankyo INC. | $47.17 | 2024 | Injectafer |
| Scynexis, INC. | $43.57 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $41.46 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $39.43 | 2019 | |
| Hologic Sales and Service, LLC | $36.94 | 2021 | |
| Celgene Corporation | $36.66 | 2024 | Zeposia |
| Shield Therapeutics INC | $27.18 | 2023 | Accrufer |
| Dexcom, INC. | $26.25 | 2025 | Dexcom G6 Transmitter |
| Pacira Pharmaceuticals Incorporated | $26.03 | 2025 | Exparel |
| Agile Therapeutics, INC. | $19.61 | 2023 | Twirla |
| Medicem INC. | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Maddock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.